Literature DB >> 19372045

Quality of life of elderly patients following valve surgery for chronic organic mitral regurgitation.

Francesco Maisano1, Giorgio Viganò, Chiara Calabrese, Maurizio Taramasso, Paolo Denti, Andrea Blasio, Andrea Guidotti, Ottavio Alfieri.   

Abstract

OBJECTIVE: Mitral valve surgery for organic mitral regurgitation (MR) in the elderly has been debated. In the elderly, quality of life is a better indicator of surgical success than survival. We assessed quality of life of elderly patients submitted to surgery for MR using the Minnesota Living with Heart Failure (MLHF) questionnaire.
METHODS: Between August 2003 and August 2006, 225 consecutive patients >70 years old underwent surgical treatment of organic MR. Mean age was 77 +/- 3.3 years (range 71-87 years). Mean EF was 50 +/- 11%. Degenerative disease was the most prevalent (77%) etiology. CABG was associated in 25% of patients. Mean Charlson score was 4.3 +/- 1.5 and 101 patients (45%) were NYHA class III and IV. Hospital survivors were followed up and quality of life by MLHF score was assessed.
RESULTS: Mitral repair and replacement were equally distributed in this population. Hospital mortality was 2.7%. Late survival was 91 +/- 1.9% at 3 years. MLHF was obtained from 204 patients at mean 2 +/- 1 years of follow-up. MLHF score was 38 +/- 18; there were 135 (66%) patients with MLHF >30. MLHF tended to increase with age at follow-up (p = 0.007). Multivariable predictors of MLHF were preoperative atrial fibrillation (p = 0.019), diabetes (p = 0.03), higher creatinine level (p = 0.0009), higher EuroSCORE (p = 0.02), residual mitral regurgitation grade at follow-up echocardiography (p < 0.0001) and systolic pulmonary artery pressure at follow-up (p = 0.04). Type of surgical treatment (repair vs replacement and choice of prosthesis) did not predict MLHF at follow-up, although those who had recurrent MR after repair had the highest scores compared to patients who had repair and durable result and those treated by replacement (MLHF was 51 +/- 21, vs 34 +/- 16, vs 39 +/- 18, respectively, p = 0.0013).
CONCLUSIONS: Quality of life following mitral valve surgery is suboptimal in more than half of elderly patients. MLHF score at follow-up is mostly related to preoperative conditions. Type of surgery does not influence MLHF score, however, quality of life is worse in patients with recurrent/residual MR following repair.

Entities:  

Mesh:

Year:  2009        PMID: 19372045     DOI: 10.1016/j.ejcts.2009.02.055

Source DB:  PubMed          Journal:  Eur J Cardiothorac Surg        ISSN: 1010-7940            Impact factor:   4.191


  5 in total

1.  Minimally invasive mitral valve surgery in octogenarians-a brief report.

Authors:  Joerg Seeburger; Matthias Raschpichler; Jens Garbade; Piroze Davierwala; Bettina Pfannmueller; Michael Andrew Borger; Friedrich-Wilhelm Mohr; Martin Misfeld
Journal:  Ann Cardiothorac Surg       Date:  2013-11

Review 2.  Treatment of degenerative mitral regurgitation in elderly patients.

Authors:  Maurizio Taramasso; Oliver Gaemperli; Francesco Maisano
Journal:  Nat Rev Cardiol       Date:  2014-12-23       Impact factor: 32.419

Review 3.  Predictors of health-related quality of life after cardiac surgery: a systematic review.

Authors:  Julie Sanders; Tracey Bowden; Nicholas Woolfe-Loftus; Mandeep Sekhon; Leanne M Aitken
Journal:  Health Qual Life Outcomes       Date:  2022-05-18       Impact factor: 3.077

4.  Interventional vs. surgical mitral valve therapy. Which technique for which patient?

Authors:  M Taramasso; N Buzzatti; G La Canna; A Colombo; O Alfieri; F Maisano
Journal:  Herz       Date:  2013-08       Impact factor: 1.443

5.  Clinical outcomes of conventional surgery versus MitraClip® therapy for moderate to severe symptomatic mitral valve regurgitation in the elderly population: an institutional experience.

Authors:  Anthony Alozie; Liliya Paranskaya; Bernd Westphal; Alexander Kaminski; Mohammad Sherif; Magnus Sindt; Stephan Kische; Jochen Schubert; Doreen Diedrich; Hüseyin Ince; Gustav Steinhoff; Alper Öner
Journal:  BMC Cardiovasc Disord       Date:  2017-03-20       Impact factor: 2.298

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.